Microalbuminuriae as a risk criterion for diabetic nephropathy development

By genetic engineering the new principle and technology for determination of proteins in the biological liquids - enzyme-linked receptor sorbent assay (ELRSA) - was developed. On its basis the tests were created for quality and quantity albumin determination in urine and for diagnosis of micrialbuminuriaeas a main criterion of diabetic nephropathy (DN) development - serious complication which leads to renal insufficiency at diabetes mellitus (DM) types I and II, requiring expensive replacement therapy. New tests effectively reveal microalbuminuriae at DM patients before the beginning of clinical stage of DN, when the treatment is accessible yet. Tests passed clinical-laboratory approbation. They can be used independently or in combination, first for semi-quantity testing of microalbuminuriae and then for diagnosis verification and opportune treatment. Tests are different from the foreign analogs. They do not need immune sera and have high specificity and sensitivity. They are accessible because of simplicity and economicity. Till now ELRSA has not been used anywhere in the world. Inculcating of new diagnostic test-systems is the only condition of their wide usage in out-patient clinical inspections with the aim to reveal microalbuminuriae among patients suffering from DM and following determination of risk groups of DN development. The screening, monitoring and treatment of patients with DN have to have positive reflection on the level of invalidity and mortality from DN and to reduce the number of expensive therapeutic procedures (haemodialysis and kidney transplantation) usually made by vital indication.